Advertisement
CTMX vs IMTX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CTMX is a StrongBuy and IMTX is a Hold.
CTMX's RSI Oscillator recovers from oversold territory
The RSI Oscillator for CTMX moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 43 similar instances when the indicator left oversold territory. In 37 of the 43 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 64 cases where CTMX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for CTMX just turned positive on October 20, 2026. Looking at past instances where CTMX's MACD turned positive, the stock continued to rise in 33 of 43 cases over the following month. The odds of a continued upward trend are 77%.
Following a +10.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where CTMX advanced for three days, in 185 of 238 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
CTMX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CTMX as a result. In 76 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The 10-day moving average for CTMX crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTMX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CTMX entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.731) is normal, around the industry mean (2.988). P/E Ratio (-4.211) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (27.624) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. CTMX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTMX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for IMTX turns positive, indicating new upward trend
IMTX saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 73 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMTX's RSI Oscillator exited the oversold zone, 22 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 41 of 52 cases where IMTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for IMTX just turned positive on October 21, 2026. Looking at past instances where IMTX's MACD turned positive, the stock continued to rise in 37 of 50 cases over the following month. The odds of a continued upward trend are 74%.
Following a +9.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMTX advanced for three days, in 221 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
IMTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for IMTX entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.929) is normal, around the industry mean (2.988). P/E Ratio (-4.836) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (23.202) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. IMTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CTMX | IMTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 68 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 27 Undervalued | 32 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 98 | |
PRICE GROWTH RATING 1..100 | 79 | 78 | |
P/E GROWTH RATING 1..100 | 98 | 24 | |
SEASONALITY SCORE 1..100 | 12 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CTMX's Valuation (27) in the Biotechnology industry is in the same range as IMTX (32) in the null industry. This means that CTMX’s stock grew similarly to IMTX’s over the last 12 months.
CTMX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as IMTX (100) in the null industry. This means that CTMX’s stock grew similarly to IMTX’s over the last 12 months.
CTMX's SMR Rating (97) in the Biotechnology industry is in the same range as IMTX (98) in the null industry. This means that CTMX’s stock grew similarly to IMTX’s over the last 12 months.
IMTX's Price Growth Rating (78) in the null industry is in the same range as CTMX (79) in the Biotechnology industry. This means that IMTX’s stock grew similarly to CTMX’s over the last 12 months.
IMTX's P/E Growth Rating (24) in the null industry is significantly better than the same rating for CTMX (98) in the Biotechnology industry. This means that IMTX’s stock grew significantly faster than CTMX’s over the last 12 months.
| CTMX | IMTX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 86% | 2 days ago 69% |
| Stochastic ODDS (%) | 2 days ago 78% | 2 days ago 79% |
| Momentum ODDS (%) | 2 days ago 88% | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 77% | 2 days ago 74% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 78% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 83% |
| Advances ODDS (%) | 3 days ago 78% | 2 days ago 76% |
| Declines ODDS (%) | 9 days ago 87% | 10 days ago 85% |
| BollingerBands ODDS (%) | 2 days ago 73% | 2 days ago 67% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CTMX’s FA Score shows that 1 FA rating(s) are green while IMTX’s FA Score has 2 green FA rating(s).
- CTMX’s FA Score: 1 green, 4 red.
- IMTX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CTMX’s TA Score shows that 5 TA indicator(s) are bullish while IMTX’s TA Score has 6 bullish TA indicator(s).
- CTMX’s TA Score: 5 bullish, 4 bearish.
- IMTX’s TA Score: 6 bullish, 2 bearish.
Price Growth
CTMX (@Biotechnology) experienced а +7.62% price change this week, while IMTX (@Biotechnology) price change was +9.86% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
CTMX is expected to report earnings on Nov 05, 2026.
IMTX is expected to report earnings on Nov 16, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IMTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMTX has been loosely correlated with SLDB. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if IMTX jumps, then SLDB could also see price increases.
| Ticker / NAME | Correlation To IMTX | 1D Price Change % | ||
|---|---|---|---|---|
| IMTX | 100% | +2.40% | ||
| SLDB - IMTX | 53% Loosely correlated | +0.16% | ||
| VIR - IMTX | 48% Loosely correlated | -1.58% | ||
| CELC - IMTX | 47% Loosely correlated | +2.60% | ||
| ABEO - IMTX | 47% Loosely correlated | -1.96% | ||
| TSHA - IMTX | 46% Loosely correlated | +0.24% | ||
More | ||||